Researchers described a vancomycin-resistant Enterococcus infection transmitted from a liver donor to recipient, ruling out hospital-acquired infection with genomics.
The company recently presented preliminary results from two large-scale studies on tracking infections and drug resistance in large hospital systems.
Danaher said that it expects the acquisition to be accretive to earnings in the fifth full year post acquisition.
The test is the 20th US-IVD molecular diagnostic on the GeneXpert menu — Cepheid also recently announced that it has now placed its 10,000 systems globally.
Lumora's MDx technology for the clinical and industrial sectors will be merged with ERBA Mannheim's IVD testing business in a wide range of market segments.
Twelve hospitals will use the company's assays to screen vulnerable patients for genes from multi-drug resistant organisms.
The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays.
In a study published in PNAS, the researchers found that the bacteria has split into three distinct species and is developing multiple clones that are highly virulent or drug resistant.
The so-called Time Machine software analyzes drug combinations and suggests candidate treatment regimens that are likely to reverse antibiotic resistance.
Using genomic and other technologies, researchers will develop tools to identify HAIs, identify patients at risk for them, and investigate more effective use of antibiotics.
Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.
The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.
The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.
In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.